Consortium Aims to Standardize IHC Biomarker Tests for Precision Medicine, Starting With HER2
The Consortium for Analytic Standardization hopes to bring an archaic technology into the 21st century by producing calibrated standards for the most utilized IHC-based biomarker tests.
Guardant Health, Thermo Fisher Scientific Tests Approved as CDx to Enhertu in Lung Cancer
The tests can now be used to identify patients with specific HER2-activating mutations that sensitize their tumors to the newly approved antibody-drug conjugate.
With recent response data galvanizing oncologists to expand access to anti-HER2 treatment, digital pathology firm Paige is ramping up efforts to create a companion test.
Agendia Building Validation Data on ImPrint for Guiding Neoadjuvant Immunotherapy in Breast Cancer
The firm envisions marketing the 53-gene signature with its existing MammaPrint and BluePrint tests as a comprehensive platform for breast cancer treatment selection.
The test is already available commercially in Spain, and the company intends to next launch its offering in Italy, as it expands to other European markets.